Giant-cell arteritis (GCA), alternatively referred to as temporal arteritis, is a form of vasculitis primarily impacting arteries, particularly those in proximity to the temples. If left untreated,...
China has become the first nation to approve Roche’s crovalimab, a paroxysmal nocturnal hemoglobinuria (PNH) treatment. Unlike AstraZeneca’s infused treatments Soliris and Ultomiris, crovalimab is administered subcutaneously. Developed by Roche’s subsidiary Chugai Pharmaceutical, crovalimab is a humanized complemen...
Find MoreGSK Receives FDA Fast Track Designation for Bepirovirsen in Chronic Hepatitis B GSK plc has revealed that the US Food and Drug Administration (FDA) has awarded Fast Track status to bepirovirsen, an experimental antisense oligonucleotide (ASO) designed to treat chronic hepatitis B (CHB). Fast Track designation ai...
Find MoreJ&J’s Cerenovus Launched Next-Gen Stroke Revascularization Catheter On February 7, 2024, Johnson & Johnson MedTech’s Cerenovus announced the launch of its next-generation CereGlide 71 intermediate catheter with TruCourse indicated for the revascularization of patients suffering from acute ischemic stroke...
Find MoreMerck’s KEYTRUDA Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Cancer (RCC) at an Increased Risk of Recurrence Following Nephrectomy Merck, also known as MSD beyond the United States and Canada, has revealed findings from the Phase III KEYNOTE-564 trial, which a...
Find MoreA month following Novartis’ foray into the paroxysmal nocturnal hemoglobinuria (PNH) treatment domain, AstraZeneca strengthens its position in this field as its latest contender, Voydeya, secures a groundbreaking approval in Japan. Voydeya (danicopan), an innovative oral factor D inhibitor, has received approval fr...
Find MoreOpdivo in Combination with CABOMETYX Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Bristol Myers Squibb and Exelixis, Inc. have released the four-year follow-up findings from the CheckMate -9ER trial, which investiga...
Find MoreFrom January 8th to 11th, 2024, the 42nd Annual J.P. Morgan Healthcare Conference (JPM24) took center stage in San Francisco, CA, USA. Spanning four dynamic days, this conference saw the active participation of prominent figures from major pharmaceutical, biotechnology, Medtech, HealthTech entities, and emerging fa...
Find MoreThe development of complement inhibitors has been growing rapidly over the years, and it has proved to be one of the breakthroughs in various therapeutic areas. These inhibitors act on the dysregulated complement system, a group of proteins that forms an essential part of innate immunity. This system comes into eff...
Find MoreDate of Abstract presentation11th December 2023IndicationsAggressive B-cell lymphoma (a-BCL)Abstract Number4459Abstract typePoster Approximately 40% of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) experience relapse following initial treatment with rituximab, cyclophosphamide, doxorubicin, vincr...
Find MoreAn autosomal metabolic disorder – Pompe disease results in deterioration of organs and tissues as .....
Find MoreSystemic Lupus Erythematosus (SLE) is an autoimmune disease where the immune system of the body mist.....
Find MoreAn autosomal recessive disorder, Ataxia Telangiectasia, affects a person's nervous system, immune sy.....
Find MoreMarket intelligence (MI) is described as the information or the data derived by a company from the m.....
Find MoreBK Virus Infection , a member of the polyomavirus family, is typically associated with patients who .....
Find MoreGene therapies are regarded as one of the potential revolution in the Pharmaceutical field and Healt.....
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.